Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIRISE-COV
- Development stage
- Preclinical
- Lead developer
- PDX Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
01
Overview
AIRISE-COV is a prophylactic vaccine candidate developed by PDX Pharmaceuticals for the prevention of COVID-19. It targets the SARS-CoV-2 antigen, acting as an inhibitor to elicit an immune response against the virus. The drug is intended for use in infectious and respiratory diseases, specifically COVID-19. As of June 2025, it remains in preclinical development and has not entered clinical trials or received regulatory approval[1][2].
- Brand names
- AIRISE-COV
- Other names
- AIRISE-COV
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on AIRISE-COV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIRISE-COV.